Advertisement

Booster dose of Pfizer’s COVID-19 vaccine neutralizes Omicron variant, company says

Click to play video: 'Pfizer says 3rd vaccine dose raises protection against Omicron variant' Pfizer says 3rd vaccine dose raises protection against Omicron variant
WATCH ABOVE: Pharmaceutical giant Pfizer claims its COVID-19 vaccine developed with BioNTech can effectively neutralize the Omicron variant after a third dose. Jamie Mauracher looks at the science of how the shot could work against the concerning variant, and what this means for people who have only had two doses – Dec 8, 2021

BioNTech and Pfizer said on Wednesday a three-shot course of their COVID-19 vaccine was able to neutralize the new Omicron variant in a laboratory test and they could deliver an Omicron-based vaccine in March 2022 if needed.

In the first official statement from vaccine manufacturers on the likely efficacy of their shot against Omicron, BioNTech and Pfizer said that two vaccine doses resulted in significantly lower neutralizing antibodies but that a third dose of their vaccine increased the neutralizing antibodies by a factor of 25.

Blood obtained from people that had their third booster shot a month ago neutralized the Omicron variant about as effectively as blood after two doses fought off the original virus first identified in China.

“Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19,” Pfizer boss Albert Bourla said in the statement.
Click to play video: 'COVID-19: Pfizer vaccine booster dose neutralizes Omicron variant, BioNTech CEO says' COVID-19: Pfizer vaccine booster dose neutralizes Omicron variant, BioNTech CEO says
COVID-19: Pfizer vaccine booster dose neutralizes Omicron variant, BioNTech CEO says – Dec 8, 2021

Read more: Omicron variant can partially evade Pfizer vaccine protection: study

Though the necessity remains unclear, the companies said they would continue their effort to bring an Omicron-specific COVID-19 vaccine to market, which they kick-started when the new lineage first raised global concern among scientists on Nov. 25.

Story continues below advertisement

A planned output of 4 billion doses of the Comirnaty vaccine in 2022 was not expected to change if an adapted vaccine was required, they added.

The findings are broadly in line with a preliminary study published by researchers at the Africa Health Research Institute in South Africa on Tuesday, saying that Omicron can partially evade protection from two doses of the Pfizer/BioNTech vaccine, suggesting also that a third shot might help fend off infection.

Click to play video: 'Mixing and matching COVID-19 vaccine boosters proves effective: study' Mixing and matching COVID-19 vaccine boosters proves effective: study
Mixing and matching COVID-19 vaccine boosters proves effective: study – Dec 3, 2021

A lab analysis at the university hospital of Frankfurt, Germany, however found a reduced antibody response to Omicron even after three shots.

The U.S.-German vaccine partners also struck an optimistic tone on the prospect of their shot protecting against any severe disease from Omicron, even though the lab data did not yield new insights on that.

Story continues below advertisement

The vast majority of surface structures on the Omicron spike protein targeted by the T-cells, which typically emerge after vaccination, are not affected by Omicron’s mutations, they said.

“The companies believe that vaccinated individuals may still be protected against severe forms of the disease,” they added.

T-cells are the second pillar of an immune response, alongside antibodies, and are believed to prevent severe disease by attacking infected human cells.

Sponsored content